Doximity acquired Amion for $74.6 million, a transaction completed in April 2022, structured as Asset acquisition - acquisition-date fair value of $74.6M, comprising $53.5M cash plus $21.1M fair value of contingent earn-out consideration. Definitive agreement provided for up to $24.0M of earn-out ($4.0M minimum guarantee + $20.0M tied to operational performance metrics) payable in cash over four years, plus ~$5M of RSUs to joining employees..
Amion operates in Physician cloud platform (Collaboration / scheduling), is based in United States (Boston-area company; serves hospitals nationwide). Doximity acquired the assets of Amion, a leading web and mobile on-call scheduling and messaging application used by hospital scheduling staff and physicians. Founded in 1998 by Stuart Karon and based in the Boston area, Amion managed nearly 200,000 physician schedules across thousands of hospitals, including 18 of the top 20.
Expanded Doximity's physician cloud platform with scheduling, enhancing its collaboration suite and driving engagement across its businesses.
Amion was already a decade-long Doximity partner with deep penetration of U.S. hospital on-call scheduling (~200,000 physician schedules, 18 of the top 20 hospitals), making it a natural, high-engagement addition to the physician cloud. Scheduling deepens Doximity's collaboration/messaging suite and increases physician engagement, which supports its Enterprise offerings. Operated as Amion, LLC within Doximity's physician cloud platform. Closed April 1, 2022 (fiscal 2023). Contingent earn-out recorded as a liability; ~$6.0M settled in Q1 FY2024. Amion, LLC remains a Doximity subsidiary.
We're excited to partner with founder Stuart Karon and the Amion team to expand our physician cloud platform. Scheduling enhances our collaboration suite and will grow engagement across all our businesses.Jeff Tangney, CEO and co-founder, Doximity
For 24 years, Amion fostered a micro-company model to maximize operational efficiency. We're excited to add Doximity's growth gene to our DNA. Formalizing our decade-long partnership will bring great new tools to many more physicians.Stuart Karon, CEO and founder, Amion
Advisory firms were not disclosed for this transaction.